PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Dept. of Intensive Care, Amsterdam UMC location AMC, Amsterdam, The Netherlands. l.atmowihardjo@amsterdamumc.nl.\', \'Dept. of Pulmonology, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.\', \'Hospital Pharmacy, Amsterdam UMC location VUMC, Amsterdam, The Netherlands.\', \'Exvastat, Cambridge, England.\', \'Simbec-Orion, Merthyr Tydfil, England.\', \'Dept. of Intensive Care, Amsterdam UMC, location VUMC, Amsterdam, The Netherlands.\', \'Dept. of Intensive Care, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands.\', \'Dept. of Intensive Care, Amsterdam UMC location AMC, Amsterdam, The Netherlands.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s13063-022-06055-9
?:hasPublicationType
?:journal
  • Trials
is ?:pmid of
?:pmid
?:pmid
  • 35172891
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.291
?:rankingScore_hIndex
  • 57
is ?:relation_isRelatedTo_publication of
?:title
  • The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35172891>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35172891>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all